Lab
Eccolab Group Co
Eccolab Group Co was paid $2.37M by Medicaid between Jan 2018 and Dec 2024, across 127 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 43% of everything it billed.
33Billing provider infoECCOLAB GROUP CO
MIAMI, FL 33144
MIAMI, FL 33144
33aNPI1831228709assigned 03/05/2007
33bProvider typeClinical Medical Laboratory
28Total paid$2.37M
24GClaims2,835,873
24DCodes billed127
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#27 of 225
Median peer was paid$74K
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 194,145 | $18K | |
| 2019 | 311,263 | $54K | |
| 2020 | 414,020 | $426K | |
| 2021 | 516,454 | $778K | |
| 2022 | 424,603 | $342K | |
| 2023 | 532,676 | $587K | |
| 2024incomplete | 442,712 | $164K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 43% | 111,133 | 31,675 | $1.01M |
| 87186 | 9.3% | 60,517 | 39,613 | $221K | |
| 80053 | Comprehensive metabolic panel | 9.1% | 207,200 | 116,514 | $216K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.9% | 142,443 | 72,719 | $116K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.4% | 72,484 | 48,123 | $105K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 300,594 | 156,338 | $71K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.7% | 32,923 | 22,273 | $64K |
| 80061 | Lipid panel | 2.0% | 71,310 | 48,282 | $47K |
| 83880 | 1.6% | 14,158 | 8,024 | $39K | |
| 82652 | 1.5% | 10,657 | 7,182 | $36K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 84,517 | 56,528 | $32K |
| 82140 | 1.3% | 25,194 | 13,647 | $30K |
115 more codes
| 80164 | 1.3% | 28,882 | $30K | |
| 82607 | 1.2% | 28,551 | $28K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.2% | 65,608 | $28K |
| 81001 | 1.1% | 73,348 | $25K | |
| 80177 | <1% | 16,018 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 83,545 | $20K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 997 | $18K |
| 80202 | <1% | 6,610 | $15K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 357,083 | $14K |
| 87088 | <1% | 64,330 | $14K | |
| 83970 | <1% | 3,708 | $11K | |
| 85610 | <1% | 57,121 | $9K | |
| 84153 | <1% | 5,671 | $9K | |
| 85027 | <1% | 41,814 | $7K | |
| 87070 | <1% | 8,177 | $7K | |
| 82728 | <1% | 11,496 | $6K | |
| 82746 | <1% | 15,848 | $6K | |
| 84134 | <1% | 1,143 | $6K | |
| 84436 | <1% | 23,385 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,100 | $5K |
| 80185 | <1% | 4,922 | $5K | |
| 83735 | <1% | 20,383 | $5K | |
| 87631 | <1% | 509 | $4K | |
| 80076 | <1% | 12,716 | $4K | |
| 81003 | <1% | 12,432 | $4K | |
| 84481 | <1% | 2,522 | $4K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 1,122 | $4K |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 455,586 | $4K |
| 84479 | <1% | 17,431 | $3K | |
| 80156 | <1% | 1,945 | $3K | |
| 82274 | <1% | 4,899 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 169 | $3K |
| 87077 | <1% | 8,254 | $2K | |
| 80184 | <1% | 1,612 | $2K | |
| 84466 | <1% | 4,592 | $2K | |
| 86140 | <1% | 8,795 | $2K | |
| 87184 | <1% | 600 | $2K | |
| 87075 | <1% | 2,751 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 551 | $2K |
| 80162 | <1% | 3,443 | $2K | |
| 84439 | <1% | 10,982 | $2K | |
| 85651 | <1% | 9,495 | $2K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 106,449 | $2K |
| 80074 | <1% | 341 | $1K | |
| 87045 | <1% | 2,127 | $1K | |
| 87205 | <1% | 10,956 | $1K | |
| 85014 | <1% | 7,910 | $1K | |
| 84480 | <1% | 4,221 | $1K | |
| 82565 | <1% | 2,377 | $1K | |
| 83540 | <1% | 6,326 | $1K | |
| 83550 | <1% | 5,370 | $1K | |
| 87106 | <1% | 811 | $967.68 | |
| 83010 | <1% | 2,677 | $688.20 | |
| 87040 | <1% | 1,440 | $683.83 | |
| 84550 | <1% | 7,189 | $637.00 | |
| 85018 | <1% | 8,377 | $634.86 | |
| 80178 | <1% | 1,343 | $620.87 | |
| 80069 | <1% | 923 | $572.11 | |
| 82040 | <1% | 2,171 | $567.12 | |
| 84132 | <1% | 1,998 | $549.31 | |
| 83721 | <1% | 1,737 | $533.80 | |
| 84100 | <1% | 5,432 | $518.16 | |
| 87481 | <1% | 713 | $505.92 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 263 | $503.84 |
| 87653 | <1% | 716 | $490.17 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 12 | $486.99 |
| 85730 | <1% | 3,331 | $474.02 | |
| 86480 | <1% | 23 | $468.58 | |
| 87324 | <1% | 884 | $468.43 | |
| 87640 | <1% | 696 | $417.20 | |
| 87493 | <1% | 2,430 | $408.34 | |
| 82550 | <1% | 1,071 | $343.93 | |
| 85044 | <1% | 3,477 | $279.35 | |
| 85379 | <1% | 489 | $247.41 | |
| 87449 | <1% | 1,087 | $239.43 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 447 | $221.40 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $208.34 |
| 81015 | <1% | 11,839 | $194.34 | |
| 83690 | <1% | 896 | $190.78 | |
| 82043 | <1% | 2,063 | $163.40 | |
| 82570 | <1% | 1,020 | $162.26 | |
| 87076 | <1% | 1,415 | $151.19 | |
| 86141 | <1% | 38 | $130.37 | |
| 80050 | General health panel | <1% | 133 | $120.20 |
| 84154 | <1% | 103 | $117.81 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 125 | $96.18 |
| 84145 | <1% | 687 | $89.23 | |
| 86769 | <1% | 163 | $85.28 | |
| 87634 | <1% | 19 | $68.80 | |
| 86038 | <1% | 74 | $68.54 | |
| 84450 | <1% | 505 | $63.38 | |
| 84520 | <1% | 232 | $59.56 | |
| 80188 | <1% | 40 | $58.79 | |
| 82150 | <1% | 415 | $54.35 | |
| 83090 | <1% | 202 | $31.89 | |
| 87177 | <1% | 96 | $26.24 | |
| 86328 | <1% | 152 | $26.20 | |
| 80175 | <1% | 37 | $25.96 | |
| 82947 | <1% | 66 | $24.68 | |
| 86592 | <1% | 16 | $23.80 | |
| 85008 | <1% | 1,388 | $19.41 | |
| 86361 | <1% | 16 | $19.22 | |
| 84156 | <1% | 128 | $17.86 | |
| 82378 | <1% | 35 | $14.22 | |
| 83615 | <1% | 146 | $12.06 | |
| 85007 | <1% | 231 | $9.01 | |
| 82310 | <1% | 41 | $8.71 | |
| 83605 | <1% | 53 | $6.25 | |
| 82465 | <1% | 18 | $2.63 | |
| 82272 | <1% | 79 | $2.57 | |
| 80150 | 0% | 96 | $0.00 | |
| 84155 | 0% | 37 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 32 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 112 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMESA, JORGE (OWNER/PRESIDET)